EyePoint Pharmaceuticals, Inc. is a high-risk pharmaceutical company based in the United States that specializes in developing and commercializing ophthalmic products for various eye diseases. With an ESG score of 39.1, the company focuses on using its Durasert E and Verisome technology platforms to deliver sustained-release treatments for conditions such as wet age-related macular degeneration and glaucoma. EyePoint Pharmaceuticals operates in the U.S., China, and the UK, generating a majority of its revenue domestically.